P8A:SGX
Cordlife Group Ltd
0,12 SGD
0,00%
(0,00) 1 d.
12. okt., 09:49:20 GMT+8 · SGD
search
Visi simboli
| Simbols | Cena | Izmaiņas | % izmaiņu |
|---|
insights_autoNotiek galveno ieskatu ģenerēšana par šādu tēmu: P8A…
Tirgus kapitalizācija
32,37 milj.
Vid. apjoms
1,32 tūkst.
Apjoms
0,00
Augstākā 52 ned.
0,26 SGD
Zemākā 52 ned.
0,10 SGD
Peļņa uz vienu akciju
-0,04 SGD
Apgrozībā esošās akcijas
267,53 milj.
Darbinieku skaits
111
Tirgus kapitalizācija
32,37 milj.
Vid. apjoms
1,32 tūkst.
Apjoms
0,00
Augstākā 52 ned.
0,26 SGD
Zemākā 52 ned.
0,10 SGD
Peļņa uz vienu akciju
-0,04 SGD
Apgrozībā esošās akcijas
267,53 milj.
Darbinieku skaits
111
Ziņas un raksti
No tīmekļa avotiem un ziņu partneriem
CryptoRank
·
pirms 9 minūtēm
Ripple and XRP Weekly Wrap: Institutional Wins, Nasdaq Debut, and Price Struggles
MarketBeat
·
pirms 40 minūtēm
The Simply Good Foods Company (NASDAQ:SMPL) Stock Now Rated "Hold" by Wall Street Brokerages
Yahoo Finance
·
pirms 1 stundas
Sandisk Is Dominating the S&P 500 in 2026. Can It Repeat in 2027?
WSJ
·
pirms 1 dienas
U.S. Stocks Fall as Credit Fears Haunt Tech Sector
Profils
Cordlife Group Limited, is a consumer health company incorporated in May 2001 and a provider of cord blood and cord lining banking services in Asia. Cordlife has been listed on the mainboard of SGX since March 2012.
Cordlife Group owns the largest network of cord blood banks in Asia with full stem cell processing and storage facilities in six markets including Singapore, Hong Kong, India, Indonesia, and the Philippines. Beyond cord blood and cord lining banking, Cordlife offers diagnostics services, particularly for the mother and child segment, including urine-based newborn metabolic screening, non-invasive prenatal testing, paediatric vision screening and family genetic screening services.
Cordlife's stem cell processing and storage facilities in Singapore, Hong Kong, India, Indonesia, the Philippines and Malaysia were accredited by AABB until 2024 when its accreditation was withdrawn.
In November 2023, the Ministry of Health of Singapore revealed that Cordlife Group had exposed cryopreserved cord blood units at suboptimal temperatures, damaging the cord blood units belonging to at least 2,150 clients and rendering them unsuitable for stem cell transplant purposes. Wikipedia
Par “Cordlife Group Ltd”
ĢenerāldirektorsYiu Pang Fai
Darbinieki111
Dibināšanas datums2001. gada 2. maijs
Galvenais birojs-
SektorsHealth care provider
Tīmekļa vietnecordlife.com